"Johnson & Johnson has agreed to pay as much as $2.2 billion to
resolve an investigation into its marketing of the anti-psychotic drug
Risperdal, according to a published report."
Read article in the Houston Chronicle (USA)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment